These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 11121077)
1. Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. Dostmann WR; Taylor MS; Nickl CK; Brayden JE; Frank R; Tegge WJ Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14772-7. PubMed ID: 11121077 [TBL] [Abstract][Full Text] [Related]
2. Exploring the mechanisms of vascular smooth muscle tone with highly specific, membrane-permeable inhibitors of cyclic GMP-dependent protein kinase Ialpha. Dostmann WR; Tegge W; Frank R; Nickl CK; Taylor MS; Brayden JE Pharmacol Ther; 2002; 93(2-3):203-15. PubMed ID: 12191612 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 reveals a novel mechanism of vasoregulation. Taylor MS; Okwuchukwuasanya C; Nickl CK; Tegge W; Brayden JE; Dostmann WR Mol Pharmacol; 2004 May; 65(5):1111-9. PubMed ID: 15102939 [TBL] [Abstract][Full Text] [Related]
4. Delineation of selective cyclic GMP-dependent protein kinase Ialpha substrate and inhibitor peptides based on combinatorial peptide libraries on paper. Dostmann WR; Nickl C; Thiel S; Tsigelny I; Frank R; Tegge WJ Pharmacol Ther; 1999; 82(2-3):373-87. PubMed ID: 10454213 [TBL] [Abstract][Full Text] [Related]
5. Culture conditions influence uptake and intracellular localization of the membrane permeable cGMP-dependent protein kinase inhibitor DT-2. Foley KF; De Frutos S; Laskovski KE; Tegge W; Dostmann WR Front Biosci; 2005 May; 10():1302-12. PubMed ID: 15769626 [TBL] [Abstract][Full Text] [Related]
6. (D)-Amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent protein kinase Ialpha. Nickl CK; Raidas SK; Zhao H; Sausbier M; Ruth P; Tegge W; Brayden JE; Dostmann WR Biochim Biophys Acta; 2010 Mar; 1804(3):524-32. PubMed ID: 20018259 [TBL] [Abstract][Full Text] [Related]
7. Endothelial dysfunction and systemic hypertension by selective cGMP-dependent protein kinase I inhibition using novel cell-penetrating peptide delivered in vivo. Poh KK; Lu P; Qin G; Silver M; Losordo DW; Mendelsohn ME; Zhu Y Int J Cardiol; 2013 Sep; 167(5):2114-9. PubMed ID: 22748498 [TBL] [Abstract][Full Text] [Related]
8. Mode of action of cGMP-dependent protein kinase-specific inhibitors probed by photoaffinity cross-linking mass spectrometry. Pinkse MWH; Rijkers DTS; Dostmann WR; Heck AJR J Biol Chem; 2009 Jun; 284(24):16354-16368. PubMed ID: 19369251 [TBL] [Abstract][Full Text] [Related]
10. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. Leung EL; Wong JC; Johlfs MG; Tsang BK; Fiscus RR Mol Cancer Res; 2010 Apr; 8(4):578-91. PubMed ID: 20371672 [TBL] [Abstract][Full Text] [Related]
11. Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Aizawa T; Wei H; Miano JM; Abe J; Berk BC; Yan C Circ Res; 2003 Sep; 93(5):406-13. PubMed ID: 12919948 [TBL] [Abstract][Full Text] [Related]
12. Protein kinase G activity prevents pathological-level nitric oxide-induced apoptosis and promotes DNA synthesis/cell proliferation in vascular smooth muscle cells. Wong JC; Fiscus RR Cardiovasc Pathol; 2010; 19(6):e221-31. PubMed ID: 20060325 [TBL] [Abstract][Full Text] [Related]
13. Peptide blockers of PKG inhibit ROS generation by acetylcholine and bradykinin in cardiomyocytes but fail to block protection in the whole heart. Krieg T; Philipp S; Cui L; Dostmann WR; Downey JM; Cohen MV Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1976-81. PubMed ID: 15591097 [TBL] [Abstract][Full Text] [Related]